What is the treatment for hyperkalemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The treatment for hyperkalemia involves a multi-modal approach, including calcium gluconate to stabilize cardiac membranes, insulin and glucose to shift potassium intracellularly, and potassium binders or loop diuretics to enhance potassium elimination, as recommended by the most recent study 1. The management of hyperkalemia depends on the severity of the condition, with mild cases potentially being managed with dietary restrictions and discontinuation of medications that increase potassium levels, while more severe cases require immediate intervention to prevent cardiac arrhythmias and other complications.

  • For acute hyperkalemia, calcium gluconate (10 mL of 10% solution IV over 2-3 minutes) is given first to stabilize cardiac membranes and prevent arrhythmias 1.
  • This is followed by insulin (10 units regular insulin IV) with glucose (25-50g IV) to shift potassium into cells temporarily, and albuterol nebulization (10-20 mg) can also help shift potassium intracellularly 1.
  • For definitive removal of potassium, sodium polystyrene sulfonate (15-30g orally or rectally) or newer potassium binders like patiromer (8.4-25.2g daily) or sodium zirconium cyclosilicate (10g three times daily initially) can be used 1.
  • Loop diuretics like furosemide (40-80mg IV) enhance potassium excretion in patients with adequate kidney function, and in severe cases or when other measures fail, hemodialysis provides rapid and effective potassium removal 1. The frequency of potassium monitoring should be individualized based on patient comorbidities and medications, particularly in patients at high risk for development of hyperkalemia, and the use of newer potassium binders may enable the optimization of renin-angiotensin-aldosterone system inhibitor therapy in more patients with hyperkalemia 1.

From the FDA Drug Label

Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia (1). Limitation of Use: Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action (1).

The treatment for hyperkalemia is Sodium Polystyrene Sulfonate Powder, for Suspension. However, it should not be used as an emergency treatment for life-threatening hyperkalemia due to its delayed onset of action 2.

  • Key points:
    • Indicated for hyperkalemia treatment
    • Not for emergency treatment of life-threatening hyperkalemia
  • This information is also supported by another study 2.

From the Research

Treatment for Hyperkalemia

The treatment for hyperkalemia involves several strategies, including:

  • Stabilizing cardiac membranes with calcium gluconate 3, 4, 5
  • Shifting potassium into cells using insulin and beta-agonists 3, 4, 6, 5
  • Eliminating excess potassium from the body through diuresis, oral binding resins, and hemodialysis 3, 4, 5
  • Correcting underlying causes, such as medication-induced hyperkalemia or metabolic acidosis 7

Emergency Treatment

In cases of severe hyperkalemia with ECG changes, emergency treatment is necessary and includes:

  • Administering calcium gluconate to stabilize cardiac membranes 3, 4, 5
  • Using intravenous insulin and inhaled beta-2 agonists to shift potassium into cells 3, 4, 6, 5
  • Initiating measures to eliminate excess potassium, such as intravenous furosemide or renal replacement therapy 3, 4, 5

Chronic Hyperkalemia Management

For chronic hyperkalemia, treatment involves:

  • Reviewing and adjusting medications that may be contributing to hyperkalemia 7
  • Ensuring effective diuretic therapy and correcting metabolic acidosis if present 7
  • Using potassium-binding drugs and sodium-glucose cotransporter 2 inhibitors to maintain potassium levels 7
  • Implementing a nuanced dietary approach, focusing on reducing nonplant sources of potassium 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment and pathogenesis of acute hyperkalemia.

Journal of community hospital internal medicine perspectives, 2011

Research

Controversies in Management of Hyperkalemia.

The Journal of emergency medicine, 2018

Research

Acute Hyperkalemia Management in the Emergency Department.

Advanced emergency nursing journal, 2024

Research

Emergency interventions for hyperkalaemia.

The Cochrane database of systematic reviews, 2005

Research

Hyperkalemia treatment standard.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.